FDA Expert on Pharmacogenomics Offers a Prescription for Progress WATERBURY, Conn., Sept. 24
WATERBURY, Conn., Sept. 24 /PRNewswire/ -- The Connecticut State Medical
Society is joining with Genomas(R), a biomedical company advancing DNA-guided
medicine and personalized healthcare, to co-sponsor a symposium -- DNA-Guided
Medicine and the Path to Personalized Health Care -- being held today at the
Society's annual meeting. Hartford Hospital is providing continuing medical
education credits for physicians attending the meeting.
Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology,
Center for Drug Evaluation and Research, U.S. Food and Drug Administration,
will discuss FDA Initiatives in Personalized Medicine: Advancing
Individualized Drug Therapy.
Dr Lesko commented: "The U.S. Department of Health and Human Services and
the FDA have prioritized personalized medicine as one of their mission goals
for public health. I am glad to participate in this event with the Connecticut
Medical Society, Hartford Hospital and Genomas to bring these initiatives to
physicians who are in an important position to implement them in their
clinical practice. Connecticut is poised to become one of the national leaders
in adoption of personalized medicine, and I am thrilled to join ranks with
these local efforts as exemplary to improving the healthcare system as a
whole."
Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, will speak
about Progress Towards DNA-Guided Medicine in Clinical Practice: Case Studies
in Cardiology and Psychiatry. Examples in these two therapeutic areas include
statins and atypical antipsychotics.
Dr. Ruano commented: "We are privileged to partner with the Connecticut
State Medical Society to convene the physicians in our state for this forum.
The presence of the FDA is an indication of the national impact of the
programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut
with Hartford Hospital and the Hospital of Central Connecticut. Together, we
are bringing personalized healthcare to our patients today, and setting the
pathway to utilization of DNA-Guided Medicine as the standard of care in
cardiovascular and psychiatric clinical practice."
ABOUT GENOMAS
Genomas Inc. is a biomedical company advancing DNA-guided medicine and
personalized healthcare. The company develops revolutionary PhyzioType(TM)
Systems for DNA-guided diagnosis and prevention of metabolic disorders induced
by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are
designed to provide physicians with the unprecedented capability to select for
each patient the safest drug treatment to enhance compliance. Genomas is
located in Hartford, CT on the campus of Hartford Hospital. For more
information, please visit www.genomas.net
ABOUT PHYZIOTYPE CLINICAL MANAGEMENT SYSTEMS
PhyzioType Systems are composed of an ensemble of inherited DNA
polymorphisms genotyped by arrays and interpreted by a biomathematical
algorithm in order to convey to physicians predicted comparisons of side
effect risk among drugs for the individual patient. To date, Genomas has
secured $3.1 million from NIH Small Business Innovation Research (SBIR) for
PhyzioType System product development.
SOURCE Genomas Inc.
